A Review of Polymyxin-B Dosage for Patients with Renal Impairment
Abstract
Since polymyxin B has a restricted therapeutic range and increased danger of both neurological damage and kidney damage, it is no longer the first choice for treating emerging gram-negative bacteria with multiple antibiotic resistance. The optimal dose schedule for patients with renal impairment regarding polymyxin B, it is provided as a chemically active formulation and primarily removed via methods other than kidney, is still up for debate. Similar to colistin, polymyxin-B effectively combats gram-negative aerobic bacterium that is resistant to several drugs such as Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli that produces carbapenemase, and Klebsiella pneumoniae. As a result, polymyxins cause cell apoptosis by inducing pan-caspase activation through many routes in a manner that is dependent on time and concentration. One of the most frequent and undesirable side effects of polymyxins is the development of AKI. A great deal of pharmacokinetic studies that have been published to far concur that creatinine clearance affects polymyxin B clearance; nevertheless, there is ongoing debate on the extent of this influence
Keywords: Polymyxin-B, kidney damage, gram-negative bacterial infection, creatinine clearance.
Keywords:
Polymyxin-B, kidney damage, gram-negative bacterial infection, creatinine clearanceDOI
https://doi.org/10.22270/jddt.v14i10.6810References
Avedissian SN, Scheetz MH, Does renal function matter for polymyxin B, Br J Clin Pharmacol, 2021;87(7):2629-2632, https://doi.org/10.1111/bcp.14675
Zakuan ZD and Suresh K, Rational use of intravenous polymyxin B and colistin: A review, Med J Malaysia, 2018; 73: 351 359.
Poirel, L., Jayol, A., and Nordmann, P., Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes, Clin. Microbial. Rev, 2017; 30: 557-596, https://doi.org/10.1128/CMR.00064-16
Couet, W., Grégoire, N., Gobin, P., Saulnier, P. J., Frasca, D., Marchand, S., et al., Pharmacokinetics of Colistin and Colistimethate Sodium after a Single 80-mg Intravenous Dose of CMS in Young Healthy Volunteers, Clin. Pharmacol Ther, 2011;89: 875-879, https://doi.org/10.1038/clpt.2011.48
Tran, T. B., Velkov, T., Nation, R. L., Forrest, A., Tsuji, B. T., Bergen, P. J., et al., Pharmacokinetics/pharmacodynamics of Colistin and Polymyxin B: Are We There yet? Int. J. Antimicrob. Agents, 2016; 48: 592-597, https://doi.org/10.1016/j.ijantimicag.2016.09.010
Tsuji BT, Pogue JM, Zavascki AP, et al., International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy, Jan 2019;39(1):10-39. https://doi.org/10.1002/phar.2209
Kwa AL, Lim TP, Low JG, et al., Pharmacokinetics of polymyxin B1 in Patients with multidrugresistant Gram-negative bacterial infections, Diagn Microbiol Infect Dis. Feb 2008;60(2):163-167, https://doi.org/10.1016/j.diagmicrobio.2007.08.008
Miglis C, Rhodes NJ, Avedissian SN, et al., Population pharmacokinetics of polymyxin B in acutely ill adult patients, Antimicrob Agents Chemother, Mar 2018;62(3): e01475-e01417, https://doi.org/10.1128/AAC.01475-17
Zavascki AP, Goldani LZ, Cao G, et al., Pharmacokinetics of intravenous polymyxin B in critically ill patients, Clin Infect Dis, Nov 15 2008;47(10):1298-1304. https://doi.org/10.1086/592577
Thamlikitkul V, Dubrovskaya Y, Manchandani P, et al., Dosing and pharmacokinetics of polymyxin B in patients with renal insufficiency, Antimicrob Agents Chemother. Jan 2017;61(1): e01337-16. https://doi.org/10.1128/AAC.01337-16
Wang M, Wei H, Zhao Y, Shang L, Di L, Lyu C and Liu J, Analysis of multidrug resistant bacteria in 3223 patients with Hospital acquired infections (HAI) from a tertiary general hospital in China, Bosn J Basic Med Sci, 2019;19: 86 93. https://doi.org/10.17305/bjbms.2018.3826
Mao T, Zhai H, Duan G and Yang H, Patterns of drug resistant bacteria in a general hospital, China, 2011 2016, Pol J Microbiol, 2019;68: 225 232. https://doi.org/10.33073/pjm-2019-024
Yue D, Song C, Zhang B, Liu Z, Chai J, Luo Y and Wu H, Hospital wide comparison of health care associated infection among 8 intensive care units: A retrospective analysis for 2010 2015, Am J Infect Control, 2017; 45: e7 e13. https://doi.org/10.1016/j.ajic.2016.10.011
Rigatto MH, Falci DR and Zavascki AP, Clinical use of polymyxin- B, Adv Exp Med Biol, 2019; 1145: 197 218. https://doi.org/10.1007/978-3-030-16373-0_14
De León Borrás R, Sánchez Sergentón C, Mayor Becerra A and Laureano Cuadrado AF, Polymyxin B for negative multidrug Resistant bacteria in a Hispanic population, P R Health Sci J, 2019; 38: 15 21.
Liang Q, Huang M and Xu Z, Early use of polymyxin B reduces the mortality of carbapenem resistant klebsiella pneumoniae Bloodstream infection, Braz J Infect Dis, 2019; 23: 60 65. https://doi.org/10.1016/j.bjid.2018.12.004
Kassamali Z, Jain R, Danziger LH, An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics, Int J Infect Dis, 2015; 30:125-132, https://doi.org/10.1016/j.ijid.2014.10.014
Rigatto MH, Vieira FJ, Antochevis LC, Behle TF, Lopes NT, Zavascki AP, Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections, Antimicrob Agents Chemother, 2015;59(10):6575-6580, https://doi.org/10.1128/AAC.00494-15
Hoeprich PD, "The Polymyxins," Med Clin North Am, 1970; 54(5):1257-65. https://doi.org/10.1016/S0025-7125(16)32591-3
Sandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., et al., Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens, CLIN. Infect. Dis, 2013; 57: 524-531. https://doi.org/10.1093/cid/cit334
Manchandani, P., Thamlikitkul, V., Dubrovskaya, Y., Babic, J. T., Lye, D. C., Lee, L.S., et al., Population Pharmacokinetics of Polymyxin B. Clin. Pharmacol. Ther, 2018; 104: 534-538, https://doi.org/10.1002/cpt.981
Evans ME, Feola DJ, Rapp RP., Polymyxin-B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria, Ann Pharmacother, 1999;33(9):960-967. https://doi.org/10.1345/aph.18426
Tan TY, Ng SY., The in-vitro activity of colistin in gram - negative bacteria, Singapore Med J,2006;47:621-4
Catchpole CR, Andrews JM, Brenwald N, wise R., A reassessment of the in-vitro activity of colistin sulphomethate sodium, J Antimicrob Chemother, 1997;39:255-60. https://doi.org/10.1093/jac/39.2.255
The Sanford guide to antimicrobial therapy, 2024.
Balli FN, Ekinci PB, Kurtaran M, et al; Battle of polymyxin induced nephrotoxicity: polymyxin B versus colistin,International journal of antimicrobial agents, 2024. https://doi.org/10.1016/j.ijantimicag.2023.107035
Li, J.; Milne, R.W.; Nation, R.L.; Turnidge, J.D.; Smeaton, T.C.; Coulthard, K., Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration, Antimicrob. agents Chemother, 2003; 47: 1766-1770. https://doi.org/10.1128/AAC.47.5.1766-1770.2003
Suzuki, T.; Yamaguchi, H.; Ogura, J.; Kobayashi, M.; Yamada, T.; Iseki, K., Megalin contributes to kidney accumulation and nephrotoxicity of colistin, Antimicrob. Agents Chemother. 2013; 57: 6319-6324. https://doi.org/10.1128/AAC.00254-13
Azad, M.A.; Akter, J.; Rogers, K.L.; Nation, R.L.; Velkov, T.; Li, J., Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells, Antimicrob. Agents Chemother, 2015; 59: 2136-2143. https://doi.org/10.1128/AAC.04869-14
Yun, B.; Zhang, T.; Azad, M.A.K.; Wang, J.; Nowell, C.J.; Kalitsis, P.; Velkov, T.; Hudson, D.F.; Li, J., Polymyxin B causes DNA damage in HK-2 cells and mice, Arch. Toxicol. 2018; 92: 2259-2271. https://doi.org/10.1007/s00204-018-2192-1
Dai, C.; Li, J.; Tang, S.; Li, J.; Xiao, X., Colistin-induced nephrotoxicity in mice involves the mitochondrial,death receptor, and endoplasmic reticulum pathways, Antimicrob. Agents Chemother, 2014; 58: 4075-4085 https://doi.org/10.1128/AAC.00070-14
Azad, M.A.; Finnin, B.A.; Poudyal, A.; Davis, K.; Li, J.; Hill, P.A.; Nation, R.L.; Velkov, T.; Li, J, Polymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells, Antimicrob. Agents Chemother, 2013; 57: 4329-4335. https://doi.org/10.1128/AAC.02587-12
Baradaran, S.; Black, D.J.; Keyloun, K.R.; Hansen, R.N.; Gillard, P.J.; Devine, B., The Impact of Acute Kidney Injury on the Risk of Mortality and Health Care Utilization Among Patients Treated with Polymyxins for Severe Gram-Negative Infections, Open Forum Infect. Dis, 2018; 5: ofy191. https://doi.org/10.1093/ofid/ofy191
Miano, T.A.; Lautenbach, E.; Wilson, F.P.; Guo, W.; Borovskiy, Y.; Hennessy, S., Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury, Clin. J. Am. Soc. Nephrol. Cjasn, 2018; 13: 542-550. https://doi.org/10.2215/CJN.06980717
Gomes, E.C.; Falci, D.R.; Bergo, P.; Zavascki, A.P.; Rigatto, M.H., Impact of polymyxin-Bassociated acute Kidney injury in 1-year mortality and renal function recovery, Int. J. Antimicrob. Agents, 2018; 52: 86-89. https://doi.org/10.1016/j.ijantimicag.2018.02.016
Meraz-Munoz, A.; Gomez-Ruiz, I.; Correa-Rotter, R.; Ramirez-Sandoval, J.C., Chronic kidney disease after Acute kidney injury associated with intravenous colistin use in survivors of severe infections: A comparative cohort study, J. Crit. Care, 2018; 44: 244-248. https://doi.org/10.1016/j.jcrc.2017.11.022
Akajagbor, D.S.; Wilson, S.L.; Shere-Wolfe, K.D.; Dakum, P.; Charurat, M.E.; Gilliam, B.L., Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 2013; 57: 1300-1303. https://doi.org/10.1093/cid/cit453
Crass, R.L.; Rutter, W.C.; Burgess, D.R.; Martin, C.A.; Burgess, D.S., Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin. Antimicrob. Agents Chemother,2017; 61: https://doi.org/10.1128/AAC.02329-16
Balkan, I.I.; Dogan, M.; Durdu, B.; Batirel, A.; Hakyemez, I.N.; Cetin, B.; Karabay, O.; Gonen, I.; Ozkan, A.S.; Uzun, S.; et al., Colistin nephrotoxicity increases with age, Scand. J. Infect. Dis, 2014; 46: 678-685. https://doi.org/10.3109/00365548.2014.926021
John, J.F.; Falci, D.R.; Rigatto, M.H.; Oliveira, R.D.; Kremer, T.G.; Zavascki, A.P., Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B, Antimicrob. Agents Chemother, 2018; 62 https://doi.org/10.1128/AAC.01617-17
Kwon, K.H.; Oh, J.Y.; Yoon, Y.S.; Jeong, Y.J.; Kim, K.S.; Shin, S.J.; Chung, J.W.; Huh, H.J.; Chae, S.L.; Park, S.Y., Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients, Incidence of Nephrotoxicity and outcomes, Int. J. Antimicrob. Agents, 2015;45: 605-609. https://doi.org/10.1016/j.ijantimicag.2015.01.011
Omrani, A.S.; Alfahad, W.A.; Shoukri, M.M.; Baadani, A.M.; Aldalbahi, S.; Almitwazi, A.A.; Albarrak, A.M., High dose intravenous colistin methane sulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia, Ann. Clin. Microbiol. Antimicrob, 2015; 14: 3. https://doi.org/10.1186/s12941-015-0062-8
Rocco, M.; Montini, L.; Alessandri, E.; Venditti, M.; Laderchi, A.; De Pascale, G.; Raponi, G.; Vitale, M.; Pietropaoli, P.; Antonelli, M., Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methane sulfonate and/or other nephrotoxic antibiotics: A retrospective cohort study, Crit. Care 2013; 17: R174. https://doi.org/10.1186/cc12853
Sorli, L.; Luque, S.; Grau, S.; Berenguer, N.; Segura, C.; Montero, M.M.; Alvarez-Lerma, F.; Knobel, H.; Benito, N.; Horcajada, J.P., Trough colistin plasma level is an independent risk factor for nephrotoxicity: A prospective observational cohort study, Bmc Infect. Dis. 2013; 13: 380. https://doi.org/10.1186/1471-2334-13-380
Goldin LAM, Silva LN, Silva TFD, Delfino VDA, Polymyxin acute kidney injury: a case of severe tubulopathy, J Bras Nefrol, 2022 Jan-Mar;44(1):112-115. https://doi.org/10.1590/2175-8239-jbn-2019-0191
Sales Gabriel Teixeira Montezuma, Foresto Renato Demarchi, Drug-induced nephrotoxicity, Revista da associacao medica brasilerira. 2020;66(Suppl.1): s82-s90. https://doi.org/10.1590/1806-9282.66.s1.82
Morales-Alvarez MC., Nephrotoxicity of antimicrobials and antibiotics, Adv chronic kidney dis, 2020 Jan;27(1):31-37. https://doi.org/10.1053/j.ackd.2019.08.001
Kaur A, Sharma GS, Kumbala DR., Acute kidney injury in diabetic patients: A narrative review, Medicine (Baltimore), 2023 May 26;102(21): e33888. https://doi.org/10.1097/MD.0000000000033888
Gauthier, T.P.; Wolowich, W.R.; Reddy, A.; Cano, E.; Abbo, L.; Smith, L.B., Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients, Antimicrob. Agents Chemother, 2012; 56: 2392-2396. https://doi.org/10.1128/AAC.00028-12
Kwon, J.A.; Lee, J.E.; Huh, W.; Peck, K.R.; Kim, Y.G.; Kim, D.J.; Oh, H.Y., Predictors of acute kidney injury associated with intravenous colistin treatment, Int. J. Antimicrob. Agents, 2010; 35: 473-477. https://doi.org/10.1016/j.ijantimicag.2009.12.002
Patschan D, Muller GA., Acute Kidney injury in diabetes mellitus, Int J Nephrol, 2016;6232909, https://doi.org/10.1155/2016/6232909
Min, K.L.; Son, E.S.; Kim, J.S.; Kim, S.H.; Jung, S.M.; Chang, M.J., Risk factors of colistin safety according to administration rou tes: Intravenous and aerosolized colistin, PLoS ONE 2018; 13: e0207588. https://doi.org/10.1371/journal.pone.0207588
Katip, W.; Uitrakul, S.; Oberdorfer P, Clinical outcomes, and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients, Infect. Drug Resist, 2017;10: 293-298. https://doi.org/10.2147/IDR.S144314
Phe, K.; Lee, Y.; McDaneld, P.M.; Prasad, N.; Yin, T.; Figueroa, D.A.; Musick, W.L.; Cottreau, J.M.; Hu, M.; Tam, V.H., In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy, Antimicrob. Agents Chemother, 2014; 58: 2740-2746. https://doi.org/10.1128/AAC.02476-13
Temocin, F.; Erdinc, S.; Tulek, N.; Demirelli, M.; Bulut, C.; Ertem, G, Incidence and Risk Factors for Colistin-Associated Nephrotoxicity, Jpn. J. Infect. Dis, 2015; 68: 318-320. https://doi.org/10.7883/yoken.JJID.2014.223
Pogue, J.M.; Lee, J.; Marchaim, D.; Yee, V.; Zhao, J.J.; Chopra, T.; Lephart, P.; Kaye, K.S., Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system, Clin. Infect. Dis. Off. Publ.Infect. Dis. Soc. Am, 2011; 53: 879-884. https://doi.org/10.1093/cid/cir611
Gul, S.; Kuscu, F.; Aydemir, H.; Ozturk, D.B.; Deveci, O.; Duygu, F.; Kacmaz, B.; Yaman, F.; Aslan, E., Risk Factors for Colistin-Associated Acute Kidney Injury: A Multicenter Study from Turkey,Jpn. J. Infect. Dis,.2016; 69: 109-112. https://doi.org/10.7883/yoken.JJID.2014.501
Kim, J.; Lee, K.H.; Yoo, S.; Pai, H., Clinical characteristics and risk factors of colistin-induced nephrotoxicity, Int. J. Antimicrob Agents, 2009; 34: 434-438. https://doi.org/10.1016/j.ijantimicag.2009.06.028
Dubrovskaya, Y.; Prasad, N.; Lee, Y.; Esaian, D.; Figueroa, D.A.; Tam, V.H., Risk factors for nephrotoxicity onset associated with polymyxin B therapy, J. Antimicrob. Chemother, 2015; 70: 1903-1907. https://doi.org/10.1093/jac/dkv014
Kubin, C.J.; Ellman, T.M.; Phadke, V.; Haynes, L.J.; Calfee, D.P.; Yin, M.T., Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy, J. Infect, 2012; 65: 80-87. https://doi.org/10.1016/j.jinf.2012.01.015
Shields, R.K.; Anand, R.; Clarke, L.G.; Paronish, J.A.; Weirich, M.; Perone, H.; Kieserman, J.; Freedy, H.;Andrzejewski, C.; Bonilla, H., Defining the incidence and risk factors of colistininduced acute kidney injury By KDIGO criteria, PLoS ONE 2017; 12: e0173286. https://doi.org/10.1371/journal.pone.0173286
Tuon, F.F.; Rigatto, M.H.; Lopes, C.K.; Kamei, L.K.; Rocha, J.L.; Zavascki, A.P., Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methane sulfonate sodium, Int. J. Antimicrob. Agents, 2014; 43: 349-352. https://doi.org/10.1016/j.ijantimicag.2013.12.002
Dai, C.; Ciccotosto, G.D.; Cappai, R.; Wang, Y.; Tang, S.; Xiao, X.; Velkov, T., Minocycline attenuates colistin-induced neurotoxicity via suppression of apoptosis, mitochondrial dysfunction, and oxidative stress, J. Antimicrob. Chemother, 2017; 72: 1635-1645. https://doi.org/10.1093/jac/dkx037
Abdelraouf K, Chang KT, Yin T, et al., Uptake of polymyxin B into renal cells, Antimicrob Agents Chemother, 2014;58(7):4200-4202. https://doi.org/10.1128/AAC.02557-14
U.S. Food and Drug Administration (2012). U.S. Food and Drug Administration. Polymyxin B. [package insert]. Available at, https://www.accessdata.fda.gov/Drugsatfda_docs/label 2012/060716Orig1s020Lbl.pdf .
Yu, M., Zou, Q., Wang, H., Zheng, S., Xu, J., Deng, X., et al. (2020), Use of Polymyxin B in Patients with Renal Impairment: A Retrospective Examination Of 5 Cases, Exp. Ther. Med, 20:89, https://doi.org/10.3892/etm.2020.9217
Rigatto MH,Falci DR, Lopes NT and Zavascki AP, Clinical features and mortality of patients on renal replacement therapy receiving polymyxin-B, Int J Antimicrob Agents , 2016;47:146150. https://doi.org/10.1016/j.ijantimicag.2015.11.007
Wang, P., Zhang, Q., Zhu, Z., Pei, H., Feng, M., Sun, T., et al., Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency, Antimicrob Agents Chemother, 2021; 65:e01900-20. https://doi.org/10.1128/AAC.01900-20
Nelson, B. C., Eiras, D. P., Gomez-Simmonds, A., Loo, A. S., Stalin, M. J., Jenkins, S. Gen et al., Clinical Outcomes Associated with Polymyxin B Dose in Patients with Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Rods, Antimicrob. Agents Chemother, 59:7000-7006, https://doi.org/10.1128/AAC.00844-15
Yu, X. B., Jiao, Z., Zhang, C. H., Dai, Y., Zhou, Z. Y., Han, L., et al., Population Pharmacokinetic and Optimization of Polymyxin B Dosing in Adult Patients with Various Renal Functions, Br. J. Clin. Pharmacol, 2021; 87:1869-1877. https://doi.org/10.1111/bcp.14576
Maniara, B. P., Healy, L. E., and Doan, T. L., Risk of Nephrotoxicity Associated with Non renally Adjusted Intravenous Polymyxin B Compared to Traditional Dosing, J. Pharm. Pract, 2020; 33: 287-292. https://doi.org/10.1177/0897190018799261
Kwa, A. L., Abdelraouf, K., Low, J. G., and Tam, V. H., Pharmacokinetics of Polymyxin B in a Patient with Renal Insufficiency: a Case Report, Clin. Infect. Dis, 2011; 52: 1280-1281. https://doi.org/10.1093/cid/cir137
Li, Y., Deng, Y., Zhu, Z.-Y., Liu, Y.-P., Xu, P., Li, X., et al., Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients, Front Pharmacol, 2021; 12: 727170. https://doi.org/10.3389/fphar.2021.727170
Wu, X., Huang, C., Wang, H., Ji, J., Ying, C., and Xiao, Y. Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China. Drug, Des Devel Ther, 2021; 15: 2593-2603. https://doi.org/10.2147/DDDT.S313714
Published
Abstract Display: 107 
PDF Downloads: 49 PDF Downloads: 29 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.